For the last few years, both Congress and the White House have attempted to limit the activities of pharmacy benefit managers (PBMs), ostensibly to limit the cost of prescription drugs. There was a fervent, but unsuccessful, push for such government mandates around the most recent government funding deadline in Washington. There have also been nearly twenty Congressional hearings focused on the industry in the last year, and there are a dozen different pieces of legislation currently being considered by a half dozen different committees.
Read Full Article »
